Galapagos NV
AEX:GLPG

Watchlist Manager
Galapagos NV Logo
Galapagos NV
AEX:GLPG
Watchlist
Price: 25.84 EUR -0.84% Market Closed
Market Cap: 1.7B EUR
Have any thoughts about
Galapagos NV?
Write Note

Galapagos NV
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Galapagos NV
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Galapagos NV
AEX:GLPG
Cash & Cash Equivalents
€52.3m
CAGR 3-Years
-64%
CAGR 5-Years
-59%
CAGR 10-Years
N/A
M
MDxHealth SA
NASDAQ:MDXH
Cash & Cash Equivalents
$21.3m
CAGR 3-Years
-12%
CAGR 5-Years
12%
CAGR 10-Years
5%
Oxurion NV
XBRU:OXUR
Cash & Cash Equivalents
€3.5m
CAGR 3-Years
-48%
CAGR 5-Years
-44%
CAGR 10-Years
N/A
Celyad Oncology SA
XBRU:CYAD
Cash & Cash Equivalents
€7m
CAGR 3-Years
-16%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
No Stocks Found

Galapagos NV
Glance View

Market Cap
1.7B EUR
Industry
Biotechnology

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 1,309 full-time employees. The company went IPO on 2005-05-06. The firm is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

GLPG Intrinsic Value
28.4 EUR
Undervaluation 9%
Intrinsic Value
Price

See Also

What is Galapagos NV's Cash & Cash Equivalents?
Cash & Cash Equivalents
52.3m EUR

Based on the financial report for Sep 30, 2024, Galapagos NV's Cash & Cash Equivalents amounts to 52.3m EUR.

What is Galapagos NV's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-59%

Over the last year, the Cash & Cash Equivalents growth was -67%. The average annual Cash & Cash Equivalents growth rates for Galapagos NV have been -64% over the past three years , -59% over the past five years .

Back to Top